Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 at 2:30 PM EDT.

Read more at globenewswire.com